USING AI AND NEUROIMAGING

ADVANCED CLINICAL TRIALS AND THERAPIES

OPTIMIZED THERAPIES

OPTIMAL MEASURES

Qynapse is a medical technology company, spin-off of the CATI consortium of neuroimaging research laboratories.

Qynapse is a medical technology company, spin-off of the CATI consortium of neuroimaging research laboratories.

OUR CLIENTS

OUR CLIENTS

PHARMAS

A solution for supporting the data-driven selection of patients, monitoring drug performance and assessing the clinical trials outcomes.

HEALTHCARE PROVIDERS

A solution that offers early and extensive insights to assist in personalizing therapies for improved patient care.

NEWS

QYNAPSE (France) and TRUE POSITIVE MEDICAL DEVICES (Canada) are partnering to provide the most advanced AI platform for brain diseases

QYNAPSE today announces the acquisition of the Canadian company TRUE POSITIVE MEDICAL DEVICES Inc. (TPMD), a spin-off from the universities of McGill and Laval – to form the most advanced artificial intelligence (AI) platform in the field of imaging of brain diseases such as Alzheimer's, Parkinson's and multiple sclerosis.

World Alzheimer's Day: Neuroimaging and artificial intelligence offer new opportunities for patients

Qynapse is strongly committed to innovation in the field of neurodegenerative diseases, particularly Alzheimer's. "By combining the latest advances in neuroimaging and artificial intelligence algorithms, our solutions represent powerful tools for the diagnosis, disease monitoring and patient care for Alzheimer's disease."

Qynapse releases new data demonstrating the value of QyScore® for the clinical assessment of Multiple Sclerosis (MS)

These results confirmed that the use of a normative database for the interpretation of brain volumetric analysis, such as the QyScore® normative database, can improve the individual assessment of brain neurodegeneration in RRMS patients in the clinical routine setting.

Qynapse sponsors the 8th joint ACTRIMS-ECTRIMS meeting – MSVirtual2020

Qynapse is excited to participate in MSVirtual2020 to share and discuss innovative and cutting-edge research in the field of Multiple Sclerosis (MS). The latest QyScore® validation and performance advances will be presented during the conference.